 Moderna
begins study of COVID-19 vaccine in kids
Send a link to a friend
[March 16, 2021]
(Reuters) - Moderna Inc has begun dosing
patients in a mid-to-late stage study of its COVID-19 vaccine,
mRNA-1273, in children aged six months to less than 12 years, the
company said on Tuesday.
|
|
 The study will assess the safety and effectiveness of two doses of
mRNA-1273 given 28 days apart and intends to enroll about 6,750
children in the United States and Canada.
The vaccine has already been authorized for emergency use in
Americans who are aged 18 and older.
In a separate study which began in December, Moderna is also testing
mRNA-1273 in adolescents between 12 and 18 years old.
[to top of second column] |
 The latest study is being
conducted in collaboration with the National
Institute of Allergy and Infectious Diseases (NIAID)
and the Biomedical Advanced Research and
Development Authority (BARDA).
(Reporting by Manojna Maddipatla in Bengaluru;
Editing by Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
